Merck, a leading science and technology company in life science, helps customers advance production capabilities while increasing access to therapies for people worldwide. The development of an ADC requires expertise in small and large molecule handling, manufacturing, formulation and testing. Choosing an experienced partner, with these skills and the required containment facilities can help advance your ADC to market. Whether you are seeking to build your process based on our tailored technology platforms, a service provider – or a combination of both, we can collaborate with you. www.MerckMillipore.com/adcservices
Multitude Therapeutics (MTX) is a preclinical-stage business unit created by Abmart to leverage its unparalleled target and antibody discovery capability for cancer immunotherapy.MTX focuses on developing novel antibody-drug conjugates (ADC) and immuno-oncology (I/O) (T cells and macrophages) based antibody therapeutics for solid and blood tumors… Read More.
At Beckman Coulter, we are dedicated to advancing and optimizing the laboratory. For more than 80 years, we have been a trusted partner for laboratory professionals, helping to advance scientific research and patient care. We have a vital role: our focus on innovation, reliability and efficiency has led us to become the partner of choice for clinical, research and industrial customers around the globe.
BlinkBio is developing a novel Tunable Drug Conjugates (TDCs) platform for the treatment of oncology and other diseases. Using proprietary SiLinkers and Payload Cassettes, TDCs employ a differentiated rapid payload release/rapid systemic clearance approach designed to drive high payload concentrations within target cells while minimizing toxicities to patients. Our business strategy is to advance selected TDCs through clinical development while partnering with major pharmaceutical and biotech companies to broaden the platform’s utility and application.
BSP Pharmaceuticals is a Contract Development and Manufacturing Organization fully dedicated to antineoplastic drugs, designed to handle the complexity of biopharmaceutical products and offering customized services to support its client from development to commercial manufacturing of injectables and oral formulations. BSP Pharmaceuticals is focused on innovative therapies such as Proteosome Inhibitors, Antibody Drug Conjugates (ADCs) , Liposomal formulations, handling the major platforms of ADC compounds currently in clinical and commercial phase.
For over 25 years, Lonza has been helping emerging biotech and pharmaceutical companies improve and advance their products. Whether you are in the early stages of clinical development or providing commercial product to patients around the globe, Lonza supplies complete development services, industry-leading manufacturing, and broad technology platforms that enable products to reach their full potential… Read More
MabPlex International provides one-stop, high-quality CRO/CMO solutions for biologics (mAb and ADCs) to our global clients. We are dedicated to help our clients accelerate development process and reduce manufacture costs. MabPlex has extensive experiences in manufacturing for therapeutic antibodies and antibody-drug conjugates (ADCs). Our manufacturing facilities with large-scale disposable lines and world-class instruments are operated by well-trained professionals in full compliance with U.S, European, and Chinese GMP regulations.
NBE-Therapeutics is a Swiss Biotechnology company developing antibody-based therapeutics. It is the main focus of NBE-Therapeutics to develop antibody drug conjugates (ADCs) for targeted cancer therapy. For this NBE-Therapeutics has developed proprietary therapeutic antibody discovery and antibody-drug conjugation technologies allowing the development of superior, “next-generation” ADCs.
Novasep provides unique services for the development and cGMP manufacture of antibody-drug conjugates including the payload, the linker and the monoclonal antibody. With a recent €10M investment in a fully integrated ADC facility, Novasep has reinforced its current ADC offering with full bio-conjugation services to meet increasing market demand.